At the board meeting on October 2022, I was elected to succeed Professor Kazutaka Shimoda and serve as the 11th president of the Japanese Society of Clinical Neuropsychopharmacology (JSCNP). During my term of office, which will last until the end of the 34th annual meeting scheduled to be held in Tokyo in 2024, I will do my utmost to guide the development of the society in cooperation with Vice President Norio Furukori and the board members, councilors, and members of the society. I look forward to working closely with each and every one of you.
The JSCNP was established on November 19, 1981 at the first meeting of the Clinical Neuropsychopharmacology Study Group at Fukushima Medical University. The aim of the JSCNP is “to develop clinical neuropsychopharmacology and improve psychiatric pharmacotherapy.” The name of the organization was changed to the Society of Clinical Neuropsychopharmacology in 1994 and the Japanese Society of Clinical Neuropsychopharmacology in 1995. The JSCNP became a general incorporated association in 2010 and currently has more than 1,500 members. The Society has produced many professors in the field of psychiatry and many excellent researchers from among its members, and its energetic activities are steadily being passed on to the younger generation.
Clinical neuropsychopharmacology is a scientific discipline that pursues the rational pharmacological treatment of psychiatric disorders by administering the right drug to the right patient group at the right dose in the right manner. To help members brush up their knowledge of psychiatric pharmacotherapy, the society discusses topics such as pharmacokinetics, pharmacodynamics, drug interactions, genomic pharmacology, treatment guidelines and algorithms for pharmacotherapy, adverse events, clinical trials, and psychotropic drug development, and many other topics related to psychiatric pharmacotherapy. We believe that cooperation with related academic societies and related fields is essential for the future activities and development of the JSCNP.
The main activities of the society include holding annual meetings, organizing seminars on clinical psychopharmacology, educating and certifying specialists in clinical neuropsychopharmacology, awarding the Paul Janssen Award for the best paper of the year, and providing overseas training programs. The educational functions of the society are particularly well-developed, with seminars on clinical neuropsychopharmacology and educational seminars on clinical psychopharmacology always dealing with clinically useful topics, and we plan to further enhance the educational content through e-learning and online seminars in the future. We have also published books such as “Clinical Neuropsychopharmacology Textbook”, “Expert Consensus on Psychiatric Pharmacotherapy,” and “Guideline for Pharmacological Therapy of Schizophrenia 2022” from the Society.
I would like to humbly ask for your support and cooperation in these endeavors.

Ken Inada
President
Japanese Society of Clinical Neuropsychopharmacology